Neurometabolic disorders are genetic disorders that disrupt how the body uses or produces energy from food. When this happens, there may be too much of some chemicals (energy from food) or too little of others that are needed to stay healthy.
This report contains market size and forecasts of Neurometabolic Disorders in Global, including the following market information:
Global Neurometabolic Disorders Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Neurometabolic Disorders market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Gaucher’s Disease Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neurometabolic Disorders include Amicus Therapeutics, ISU Abxis, JCR Pharmaceuticals, Biosidus, Greenovation Biotech, UAB Proforma, Dong-A Socio Group, ExSAR Corporation and Lixte Biotechnology, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurometabolic Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurometabolic Disorders Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Neurometabolic Disorders Market Segment Percentages, by Type, 2021 (%)
Gaucher’s Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis VI
Other
Global Neurometabolic Disorders Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Neurometabolic Disorders Market Segment Percentages, by Application, 2021 (%)
Oral
Parenteral
Global Neurometabolic Disorders Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Neurometabolic Disorders Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurometabolic Disorders revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Neurometabolic Disorders revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amicus Therapeutics
ISU Abxis
JCR Pharmaceuticals
Biosidus
Greenovation Biotech
UAB Proforma
Dong-A Socio Group
ExSAR Corporation
Lixte Biotechnology
Neuraltus Pharmaceuticals
Protalix
Pharming Group
Protalix BioTherapeutics
Amicus
Biomarin
Genzyme
Shire
Greencross